Changes in dopamine-mediated behaviour during one year's neuroleptic administration

European Journal of Pharmacology
A ClowC D Marsden


Trifluoperazine (2.5--3.5 mg/kg/day) or thioridazine (30--40 mg/kg/day) were given in the drinking water to male Wistar rats for 12 months. Initial catalepsy and inhibition of spontaneous locomotion disappeared by 3 months and thereafter. Initial inhibition of stereotypy induced by s.c. apomorphine also disappeared by 3 months to be replaced by an enhanc-d stereotypy response after 6 and 12 months' drug intake. Drug-treated animals exhibited a greatly increased incidence of spontaneous mouth movements after 12 months' intake compared with control animals. Lower doses of both drugs (trifluoperazine 0.7--0.9 mg/kg/day; thioridazine 6--8 mg/kg/day) also initially suppressed behavioural responses but by 1 month and thereafter these animals were indistinguishable from controls. At 12 months, however, these animals also exhibited an increased incidence of spontaneous mouth movements. The data demonstrate a reversal of the initial dopamine receptor-blocking properties of trifluoperazine or thioridazine to be replaced by an enhanced response of cerebral dopamine systems while animals were still continuously receiving the drug.


Oct 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·A J StoesslH Frydryszak
Jan 1, 1983·Psychopharmacology·N BjørndalE Christensson
Jan 1, 1989·Psychopharmacology·J N NobregaH T Barros
Jan 1, 1982·Psychopharmacology·D E CaseyN Bjørndal
May 1, 1983·Naunyn-Schmiedeberg's Archives of Pharmacology·K J Dewey, H C Fibiger
Jan 1, 1990·Psychopharmacology·C SchremmerT Ott
May 16, 2009·Journal of Neural Transmission·Santhrani Thaakur, G Himabindhu
Dec 17, 1981·European Journal of Pharmacology·C H MisraR C Smith
Feb 19, 1981·European Journal of Pharmacology·J L WaddingtonR C Bourne
Apr 23, 1982·European Journal of Pharmacology·C PycockC O'Shaughnessy
Nov 13, 1990·European Journal of Pharmacology·B GlenthøjT G Bolwig
Feb 29, 1996·European Journal of Pharmacology·J Van KampenA J Stoessl
Dec 1, 1986·Pharmacology, Biochemistry, and Behavior·L A RodriguezM L Camarena
Feb 1, 1990·Pharmacology, Biochemistry, and Behavior·P M CarveyH L Klawans
Aug 1, 1991·Pharmacology, Biochemistry, and Behavior·K LeebR Eikelboom
Jul 1, 1991·Pharmacology, Biochemistry, and Behavior·R M Kostrzewa, L Gong
Jan 1, 1991·Pharmacology, Biochemistry, and Behavior·R M Kostrzewa, A Hamdi
Aug 1, 1993·Pharmacology, Biochemistry, and Behavior·H RosengartenA J Friedhoff
Sep 1, 1993·Pharmacology, Biochemistry, and Behavior·P M CarveyJ Z Fields


Oct 1, 1977·Biochemical Pharmacology·P Seeman
Dec 15, 1978·Psychopharmacology·P Muller, P Seeman
Aug 16, 1977·Psychopharmacology·B WeissG Lusink
May 1, 1976·European Journal of Pharmacology·B J SahakianS D Iversen
Nov 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·P SeemanK Wong
Aug 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·J W KebabianP Greengard
Jan 11, 1974·Psychopharmacologia·B Fjalland, I Moller Nielsen
Jan 1, 1970·Annual Review of Pharmacology·B L Mirkin

Related Concepts

Antipsychotic Effect
Behavior, Animal
Antipsychotic Agents
Vestibule of Mouth
Dyskinesia, Medication-Induced

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here